Management of neuropathic pain is a real clinical challenge. Current treatments focus on blocking neurotransmission and do not differentiate between different phases of neuropathic pain pathophysiology. The authors have recently shown that nerve-injury-induced neuropathic pain development requires matrix metalloprotease-9 and -2 (MMP-9 and MMP-2) in the early and late phase, respectively. Inhibition of MMP-9 or MMP-2 may provide a novel therapeutic approach for the treatment of neuropathic pain at different phases.
Neuropathic pain is often characterized by spontaneous pain, described as shooting, lancinating, or burning pain, and also by evoked pain, such as hyperalgesia (increased responsiveness to noxious stimuli) to mechanical and thermal stimuli. Probably the most distinct symptom of neuropathic pain is mechanical allodynia (painful responses to normally innocuous tactile stimuli). For example, patients feel enormous pain during movement. Currently available drugs such as tricyclic antidepressants, anticonvulsants, sodium channel blockers, N-methyl-D-aspartate (NMDA) receptor antagonists, and opioids provide relief from neuropathic pain in only a fraction of such patients, with severe side effects. 2, 3 This failure results in part from the strategy of these drugs to block neurotransmission, ignoring the underlying pathology of neuropathic pain. Therefore, pain relief after many treatments often lasts no longer than the drug's presence at the site.
Neuropathic pain research has been accelerated with different animal models in which the sciatic nerve and its branches, or the spinal nerves, or the spinal cord are intentionally damaged. 1, 4 How well these different injury models include the clinically presenting pain syndromes remains an important concern for validating common mechanisms and establishing animal models for human drug testing. However, clinical cases are often difficult to study because there are multiple contributing factors and the time from the initial insult, when it is recognized, can vary from several days, to weeks, to years.
Thus, most mechanistic studies are based on animal models. 12 These cytokines can also produce long-term effects on synaptic plasticity by inducing gene transcription. 12 However, how these cytokines are activated after nerve injury is unclear.
IL-1β is synthesized as a precursor (31kDa) and subsequently cleaved into a partially processed form (28kDa) and a completely processed or mature form (17kDa). The precursor form of IL-1β shows little or no biological activity. Intracellular IL-1β consists exclusively of the precursor form.
Although caspase-1, also known as IL-1β-converting enzyme, is a welldocumented protease for IL-1β activation, other enzymes such as trypsin, elastase, collagenase, and metalloprotease are also implicated in IL-1β
cleavage. 13 It is worthwhile to mention that under several inflammatory conditions, caspase-1-deficient mice can still mediate IL-1β-dependent reactions and produce the same level of bioactive IL-1β.
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Neuropathic Pain Phases
Different phases of neuropathic pain have not been clearly defined so far, and these phases may vary under different injury conditions. However, there are at least two phases in animal models: an early phase (first several days) when neuropathic pain is developed, and a late phase (from a week to months and even years) when neuropathic pain is maintained.
It appears that, after nerve injury, microglia activation (e.g. upregulation of the microglial markers CD11b and Iba1) in the spinal cord peaks in the early phase but declines in the late phase, as does the activation of p38 MAPK in spinal microglia. 9 Therefore, the analgesic efficacy of spinal injection of p38 inhibitor reduces in the late phase. 8 Furthermore, minocycline, a microglial inhibitor, attenuates neuropathic pain in the early phase but not in the late phase. 7 In contrast, astrocyte activation accompanies chronic CNS injury. 21 Depending on whether functional or dysfunctional remodeling occurs, the result might be recovery or the induction of aberrant neuronal circuits, some of which may be involved in the generation of pain.
Matrix Metalloprotease-9 and Early-phase Neuropathic Pain
Spinal nerve ligation (SNL) at the L5 level is known to produce rapid (less than one day) and persistent (>21 days) neuropathic pain symptoms (e.g. mechanical allodynia) in rats and mice. 4, 22 The authors used gelatin zymography to check MMP-9 activity and expression in the L5 dorsal root ganglia (DRG) collected from naive animals and injured animals (six hours to (more than three days) upregulation of MMP-9 in the DRG. Furthermore, MMP-9 expression increases in DRG neurons on day one. 22 To define the specific role of MMP-9 in neuropathic pain development, the authors employed five different approaches:
• small synthetic inhibitor of MMP-9;
• endogenous peptide inhibitor of MMP-9 (TIMP-1);
• small interfering RNA against MMP-9;
• exogenous MMP-9 injection; and
• MMP-9 knockout mice.
To avoid systemic effects of drugs, the authors delivered these drugs into spinal fluid via intrathecal administration to target MMP-9 in the DRG and spinal cord. Results from these five different approaches are very consistent,
showing that MMP-9 inhibition or deletion can attenuate neuropathic pain in the early phase. Conversely, intrathecal injection of exogenous MMP-9 is sufficient to induce mechanical allodynia. In particular, the endogenous inhibitor TIMP-1 is 1,000 times more potent than morphine, a commonly used analgesic to treat neuropathic pain, and the duration of pain suppression by TIMP-1 is also 10 times longer than that of morphine.
However, this powerful inhibitor only works in the early phase (e.g. day one), not in the late phase (e.g. day 10).
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The authors have further explored the mechanisms by which MMP-9 induces neuropathic pain. SNL induces a marked IL-1β activation (cleavage) in the DRG in the early phase (day one), which is lost in mice lacking Mmp9, suggesting that MMP-9 is needed for IL-1β activation after nerve injury. Injection of MMP-9 is also sufficient to induce IL-1β activation in the DRG. Furthermore, MMP-9 and IL-1β are co-expressed in the same neurons in the DRG. 22 The authors hypothesize that nerve-injury-induced spontaneous discharge in sensory neurons can release MMP-9 and pro-IL-1β into the ECM, where MMP-9 cleaves pro-IL-1β to produce active IL-1β.
The active IL-1β then acts on adjacent nociceptive neurons to produce hyperexcitability. The authors' behavioral studies show that blocking IL-1β with a neutralizing antibody can suppress neuropathic pain symptoms induced either by MMP-9 or by nerve injury, supporting an important role of the MMP-9/IL-1β cascade in neuropathic pain development. Finally, MMP-9 in DRG soma is transported to central terminals in the dorsal horn to activate microglia. At the spinal level, MMP-9 is sufficient to activate microglia even in a low dose that does not produce demyelination and apoptosis. 22 Collectively, MMP-9 induces early-phase neuropathic pain by activating IL-1β and microglia in the early phase.
Matrix Metalloprotease-2 and Late-phase Neuropathic Pain
Nerve injury also induces an upregulation of MMP-2, but the induction pattern of MMP-2 is quite different from that of MMP-9:
• in contrast to a rapid and transient upregulation of MMP-9, SNL produces a delayed (more than seven-day) and persistent (>21-day) upregulation of MMP-2 in the DRG;
• while MMP-9 is induced in DRG neurons, MMP-2 is induced in small satellite cells surrounding DRG neurons; and
• although MMP-9 activity in the spinal cord is low even after nerve injury, in part due to rapid release from central terminals, MMP-2 upregulation is persistently induced in spinal cord astrocytes. 22 Satellite cells in the DRG and astrocytes in the spinal cord share some similar features: they both show persistent upregulation of GFAP and pERK after nerve injury and contribute to the maintenance of neuropathic pain.
Of interest, MMP-9 is not necessary for MMP-2 upregulation, since SNL still upregulates MMP-2 even in Mmp9 knockout mice.
To determine the role of MMP-2 in late-phase neuropathic pain, three different pharmacological approaches were used:
• small synthetic inhibitor of MMP-2;
• endogenous peptide inhibitor of MMP-2 (TIMP-2); and
• small interfering RNA against MMP-2 to block MMP-2 in the late phase.
The data consistently show that MMP-2 inhibition can very effectively attenuate neuropathic pain in the late phase. In contrast, injection of exogenous MMP-2 is able to induce neuropathic pain symptoms. Minocycline may also be used to prevent neuropathic pain after trauma and major surgeries. ■
